Jazz Pharmaceuticals Officer Files Form 144 for $1.3M Planned Sale

Executive Summary

On November 2, 2026, Bruce C Cozadd, an Officer of Jazz Pharmaceuticals plc ($JAZZ), submitted a Form 144 filing indicating the proposed sale of 6,000 ordinary/common shares with an estimated aggregate market value of $1,295,040 (implied price of ~$215.84 per share). The transactions are to be executed through Merrill Lynch.

Transaction & Plan Details

• Securities to be Sold: 6,000 Common Shares acquired on March 5, 2025, via Stock Option exercise from the issuer paid in cash.
• 10b5-1 Plan Status: The proposed sale is executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 26, 2025.
• Prior 3-Month Activity:
  • October 1, 2026: Sold 6,000 shares for gross proceeds of $1,381,980.
  • September 1, 2026: Sold 6,000 shares for gross proceeds of $1,500,780.
  • August 3, 2026: Sold 6,000 shares for gross proceeds of $1,517,880.

Trading Significance Assessment

The trading significance is rated as Low. The proposed transaction represents regular, programmatic monthly dispositions of 6,000 shares under a pre-scheduled Rule 10b5-1 trading plan adopted nearly a year prior. It represents a negligible fraction of the company's 64,914,577 total outstanding shares.